Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abraxane sNDA Is 505(b)(2) Test, But Panel Has Efficacy, Labeling Questions

Executive Summary

One obstacle to using the 505(b)(2) pathway for approving efficacy supplements appears to be how to characterize an agent's effectiveness in labeling
Advertisement

Related Content

Pfizer Seeks To Block 505(b)(2) Label Expansions For Lumigan, Travatan
Pfizer Seeks To Block 505(b)(2) Label Expansions For Lumigan, Travatan
505(b)(2) Standards Needed To Ensure Predictability – Pfizer Attorney
505(b)(2) Standards Needed To Ensure Predictability – Pfizer Attorney
505(b)(2) Standards Needed To Ensure Predictability – Pfizer Attorney
Advertisement
UsernamePublicRestriction

Register

PS047545

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel